Tag Archive for: Hansa Biopharma

Weekly roundup: Industry events, gender and GLP-1s, highlighting Rare Disease Day

/in

Novo Nordisk Foundation announced it had awarded DKK 11.8 billion (€1.6 billion) during 2025 to support more than 2,200 projects aimed at improving people’s health and the sustainability of society and the planet. The projects cover the full range of the Foundation’s grant-giving areas, including key topics such as cardiometabolic diseases, antimicrobial resistance, the development of more resilient and climate-friendly […]

Read more

Hansa Biopharma presenting at TD Cowen’s 46th Annual Health Care Conference

/in

Lund, Sweden, 23 February, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at TD Cowen’s 46th Annual Health Care Conference in Boston, at 11:10-11:40 AM EST on Monday 2 March, 2026. Hansa Biopharma CFO Evan Ballantyne, and COO and President U.S. Maria Törnsén, will […]

Read more

Weekly roundup: From awards and appointments to Women in Science Day and the launch of the European Life Sciences Coalition

/in

European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem The European Life Sciences Coalition (ELSC)  launched this week to strengthen Europe’s life sciences and biotechnology VC ecosystem by mobilising greater levels of private and public investment across the sector. Created in association with Invest Europe, the coalition brings together leading European life […]

Read more

Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

/in

· Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. · Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation. · Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M). Lund, Sweden, 11 February 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its […]

Read more